References
1. Comeau AM, Accurso FJ, White TB, Campbell PW, Hoffman G, Parad RB, Wilfond BS, Rosenfeld M, Sontag MK, Massie J, et al. Guidelines for implementation of cystic fibrosis newborn screening programs: Cystic Fibrosis Foundation workshop report. Pediatrics 2007; 119: e495-518.
2. Wagener JS, Zemanick ET, Sontag MK. Newborn screening for cystic fibrosis. Curr Opin Pediatr 2012; 24: 329-335.
3. Kloosterboer M, Hoffman G, Rock M, Gershan W, Laxova A, Li Z, Farrell PM. Clarification of laboratory and clinical variables that influence cystic fibrosis newborn screening with initial analysis of immunoreactive trypsinogen. Pediatrics 2009; 123: e338-346.
4. Rock MJ, Mischler EH, Farrell PM, Wei LJ, Bruns WT, Hassemer DJ, Laessig RH. Newborn screening for cystic fibrosis is complicated by age-related decline in immunoreactive trypsinogen levels.Pediatrics 1990; 85: 1001-1007.
5. Travert G, Heeley M, Heeley A. History of Newborn Screening for Cystic Fibrosis-The Early Years. Int J Neonatal Screen 2020; 6: 8.
6. Sontag MK, Wright D, Beebe J, Accurso FJ, Sagel SD. A new cystic fibrosis newborn screening algorithm: IRT/IRT/DNA. J Pediatr2009; 155: 618-622.
7. Therrell BL, Hannon WH, Hoffman G, Ojodu J, Farrell PM. Immunoreactive Trypsinogen (IRT) as a Biomarker for Cystic Fibrosis: challenges in newborn dried blood spot screening. Mol Genet Metab2012; 106: 1-6.
8. Cystic Fibrosis Foundation Patient Registry 2020 Annual Data Report. Bethesda, Maryland; 2020.
9. Martiniano SL, Elbert AA, Farrell PM, Ren CL, Sontag MK, Wu R, McColley SA. Outcomes of infants born during the first 9 years of CF newborn screening in the United States: A retrospective Cystic Fibrosis Foundation Patient Registry cohort study. Pediatr Pulmonol 2021; 56: 3758-3767.
10. Bobadilla JL, Macek M, Fine JP, Farrell PM. Cystic fibrosis: a worldwide analysis of CFTR mutations–correlation with incidence data and application to screening. Hum Mutat 2002; 19: 575-606.
11. Watts KD, Layne B, Harris A, McColley SA. Hispanic Infants with cystic fibrosis show low CFTR mutation detection rates in the Illinois newborn screening program. J Genet Couns 2012; 21: 671-675.
12. Pique L, Graham S, Pearl M, Kharrazi M, Schrijver I. Cystic fibrosis newborn screening programs: implications of the CFTR variant spectrum in nonwhite patients. Genet Med 2017; 19: 36-44.
13. Sugarman EA, Rohlfs EM, Silverman LM, Allitto BA. CFTR mutation distribution among U.S. Hispanic and African American individuals: evaluation in cystic fibrosis patient and carrier screening populations.Genet Med 2004; 6: 392-399.
14. Grody WW, Cutting GR, Klinger KW, Richards CS, Watson MS, Desnick RJ. Laboratory standards and guidelines for population-based cystic fibrosis carrier screening. Genet Med 2001; 3: 149-154.
15. Watson MS, Cutting GR, Desnick RJ, Driscoll DA, Klinger K, Mennuti M, Palomaki GE, Popovich BW, Pratt VM, Rohlfs EM, et al. Cystic fibrosis population carrier screening: 2004 revision of American College of Medical Genetics mutation panel. Genet Med 2004; 6: 387-391.
16. Baker MW, Atkins AE, Cordovado SK, Hendrix M, Earley MC, Farrell PM. Improving newborn screening for cystic fibrosis using next-generation sequencing technology: a technical feasibility study. Genet Med2016; 18: 231-238.
17. Sicko RJ, Stevens CF, Hughes EE, Leisner M, Ling H, Saavedra-Matiz CA, Caggana M, Kay DM. Validation of a Custom Next-Generation Sequencing Assay for Cystic Fibrosis Newborn Screening. Int J Neonatal Screen 2021; 7: 73.
18. Martiniano SL, Croak K, Bonn G, Sontag MK, Sagel SD. Improving outcomes for Colorado’s IRT-IRT-DNA cystic fibrosis newborn screening algorithm by implementing floating cutoffs. Mol Genet Metab 2021; 134: 65-67.
19. McMahon R, DeMartino L, Sowizral M, Powers D, Tracy M, Caggana M, Tavakoli NP. The Impact of Seasonal Changes on Thyroxine and Thyroid-Stimulating Hormone in Newborns. Int J Neonatal Screen2021; 7: 8.
20. Laboratories AoPH. Overview of Cutoff Determinations and Risk Assessment Methods used in Dried Blood Spot Newborn Screening- Role of Cutoffs and Other Methods of Data Analysis. 2017. https://www.aphl.org/programs/newborn_screening/Documents/ Overview%20on%20Cutoff%20Determinations%20and%20RIsk%20Assessment%20Methods_final.pdf. [accessed 7/31/22].
21. Sosnay PR, Salinas DB, White TB, Ren CL, Farrell PM, Raraigh KS, Girodon E, Castellani C. Applying Cystic Fibrosis Transmembrane Conductance Regulator Genetics and CFTR2 Data to Facilitate Diagnoses.J Pediatr 2017; 181S: S27-S32.e21.
22. Taussig LM, Boat TF, Dayton D, Fost N, Hammond K, Holtzman N, Johnson W, Kaback MM, Kennel J, Rosenstein BJ, et al. Neonatal Screening for Cystic Fibrosis: Position Paper. Pediatrics 1983; 72: 741-745.
23. Padoan R, Genoni S, Moretti E, Seia M, Giunta A, Corbetta C. Genetic and clinical features of false-negative infants in a neonatal screening programme for cystic fibrosis. Acta Paediatr 2002; 91: 82-87.